Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval · Investor's Business Daily ALLISON GATLIN Thu, Dec 19, 2024, 2:21 PM 2 min read In This Article: MEOBF MESO Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed. Continue Reading View Comments Terms and Privacy Policy Your Privacy Choices Utah Privacy Notice Recommended Stories